Figure 5

SLT-1A^IYSNKLM generates modest IgG immune responses in CD1 mice. (A) Injection schedule of SLT-1A^IYSNKLM with and without adjuvant. Treatments consisted of i.v. injections of SLT-1A^IYSNKLM prepared in saline into CD1 mice as a series of 5 consecutive (daily) tail vein injections or a single s.c. injection of SLT-1A^IYSNKLM in Complete Freund's adjuvant (CFA) followed by two s.c. boosts of the antigen in Incomplete Freund's adjuvant (IFA) at days 21 and 35. (B) Histogram illustrating the average IgG immune responses (1:1000 titer dilution) from 3 CD1 mice injected with SLT-1A^IYSNKLM in the presence (black bars) or absence of adjuvant (white bars) as measured by ELISA at 405 nm. (C) Representative IgG immune responses (average ELISA signals at 405 nm versus antisera titers; day 42) engendered for groups of three CD1 mice after injection with SLT-1A^IYSNKLM in the presence (white circles) or absence of adjuvant (black circles). Data represent the s.e.m. of experiments performed in triplicate.